The overactive bladder in children: a potential future indication for tolterodine.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Mogren K.) > The overactive blad...

Details
MARC

Hjälmås, Kelm,1933Gothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna, Avdelningen för urologi,Institute of Surgical Sciences, Department of Urology (author)

The overactive bladder in children: a potential future indication for tolterodine.

Article/chapterEnglish2001

Publisher, publication year, extent ...

2001

Numbers

LIBRIS-ID:oai:gup.ub.gu.se/72083
https://gup.ub.gu.se/publication/72083URI

Supplementary language notes

Language:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

OBJECTIVE: To determine the safety, efficacy and pharmacokinetics of tolterodine in children with an overactive bladder. PATIENTS AND METHODS: Thirty-three children (20 boys and 13 girls, aged 5-10 years) with an overactive bladder and symptoms of urgency, frequency and/or urge incontinence were enrolled in an open, dose-escalation study. Patients were treated with oral tolterodine 0.5 mg (n = 11), 1 mg (n = 10) or 2 mg (n = 12) twice daily for 14 days. The primary safety endpoint was the change in residual urinary volume, as determined by ultrasonography. In addition, voiding diary variables (frequency and incontinence episodes) and pharmacokinetics were evaluated. Other safety endpoints included laboratory variables, electrocardiogram recordings and reported adverse events. RESULTS: There were no safety concerns in terms of the change in residual urinary volume for any of the three dosage groups; values were comparable with baseline after 2 weeks of treatment for all three dosages. Adverse events were reported by 20 patients (six on 0.5 mg, five on 1 mg, and nine on 2 mg). Most adverse events were not considered to be drug-related; of the 13 possibly related events, 10 occurred in those taking 2 mg. Headache was the most commonly reported adverse event. No serious adverse events were reported and there were no general safety concerns. There was an improvement in voiding diary variables in all treatment groups after 2 weeks of treatment, although the efficacy was greatest in those taking 1 mg and 2 mg. Pharmacokinetic findings were consistent with dose linearity over the range 0.5-2 mg. CONCLUSION: The results support the use of 1 mg twice daily as the optimal dose of tolterodine for treating children aged 5-10 years with an overactive bladder.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Farmaceutiska vetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Pharmaceutical Sciences hsv//eng
SAMHÄLLSVETENSKAP Annan samhällsvetenskap Övrig annan samhällsvetenskap hsv//swe
SOCIAL SCIENCES Other Social Sciences Other Social Sciences not elsewhere specified hsv//eng
Administration
Oral
Benzhydryl Compounds
administration & dosage
adverse effects
pharmacokinetics
Child
Child
Preschool
Cresols
administration & dosage
adverse effects
pharmacokinetics
Dose-Response Relationship
Drug
Female
Humans
Male
Muscarinic Antagonists
administration & dosage
adverse effects
pharmacokinetics
Phenylpropanolamine
Urinary Incontinence
drug therapy

Added entries (persons, corporate bodies, meetings, titles ...)

Hellström, Anna-Lena,1946Gothenburg University,Göteborgs universitet,Institutionen för omvårdnad,Institutionen för kvinnors och barns hälsa, Avdelningen för pediatrik,Institute of Nursing,Institute for the Health of Women and Children, Dept of Paediatrics(Swepub:gu)xhannx (author)
Mogren, KGothenburg University,Göteborgs universitet,Institutionen för kvinnors och barns hälsa,Institute for the Health of Women and Children (author)
Läckgren, G (author)
Stenberg, A (author)
Göteborgs universitetInstitutionen för de kirurgiska disciplinerna, Avdelningen för urologi (creator_code:org_t)

Related titles

In:BJU international87:6, s. 569-741464-4096

Internet link

https://gup.ub.gu.se/publication/72083

Find in a library

BJU international (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Hjälmås, Kelm, 1 ...; Hellström, Anna- ...; Mogren, K; Läckgren, G; Stenberg, A

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Pharmaceutical S ...

SOCIAL SCIENCES: SOCIAL SCIENCES; and Other Social Sci ...; and Other Social Sci ...

Articles in the publication: BJU internationa ...

By the university: University of Gothenburg

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se